metolazone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1783 17560-51-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • SR72022
  • zaroxolyn
  • metolazone
  • metozalone
Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.
  • Molecular weight: 365.83
  • Formula: C16H16ClN3O3S
  • CLOGP: 2.06
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 92.50
  • ALOGS: -3.95
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.78 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 65 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 1973 FDA UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fluid retention 246.41 16.51 164 14584 50485 50539891
Cardiac failure congestive 236.43 16.51 196 14552 84186 50506190
Hypervolaemia 235.73 16.51 125 14623 25374 50565002
Pulmonary arterial hypertension 229.48 16.51 114 14634 20205 50570171
Right ventricular failure 170.10 16.51 86 14662 15807 50574569
Dyspnoea 139.57 16.51 411 14337 547197 50043179
Drug ineffective 119.97 16.51 45 14703 819288 49771088
Pulmonary hypertension 106.92 16.51 84 14664 33333 50557043
Acute kidney injury 98.76 16.51 210 14538 227848 50362528
Oedema 92.43 16.51 108 14640 70073 50520303
Oedema peripheral 92.15 16.51 165 14583 157796 50432580
Calcium deficiency 70.20 16.51 21 14727 929 50589447
Electrolyte imbalance 70.17 16.51 50 14698 17119 50573257
Death 62.22 16.51 222 14526 325157 50265219
Gastrointestinal haemorrhage 60.94 16.51 90 14658 73231 50517145
Acute respiratory failure 58.78 16.51 56 14692 28726 50561650
Dyspnoea exertional 57.90 16.51 73 14675 51160 50539216
Cardiac failure acute 55.87 16.51 33 14715 8217 50582159
Off label use 55.54 16.51 35 14713 474391 50115985
Renal failure 54.10 16.51 105 14643 106528 50483848
Hospitalisation 53.04 16.51 81 14667 67856 50522520
Hypoxia 51.76 16.51 69 14679 51054 50539322
Cardiac failure 50.22 16.51 84 14664 75956 50514420
Pulmonary oedema 49.47 16.51 66 14682 48872 50541504
Atrial fibrillation 48.96 16.51 98 14650 101647 50488729
Hypokalaemia 48.78 16.51 90 14658 87902 50502474
Chronic kidney disease 43.87 16.51 56 14692 39715 50550661
Hypotension 43.51 16.51 159 14589 235310 50355066
Torsade de pointes 42.76 16.51 32 14716 11803 50578573
Transfusion 42.46 16.51 33 14715 12872 50577504
Rheumatoid arthritis 41.79 16.51 5 14743 202545 50387831
Gout 41.41 16.51 31 14717 11439 50578937
Hyperkalaemia 41.34 16.51 60 14688 48029 50542347
Dermatitis exfoliative 41.33 16.51 23 14725 5119 50585257
BRASH syndrome 40.89 16.51 10 14738 203 50590173
Respiratory failure 39.36 16.51 84 14664 91097 50499279
Blood potassium decreased 39.14 16.51 51 14697 36894 50553482
Ascites 38.77 16.51 50 14698 35811 50554565
Cor pulmonale 38.49 16.51 16 14732 1871 50588505
Cholecystitis 38.27 16.51 32 14716 13839 50576537
Arthralgia 38.24 16.51 43 14705 438659 50151717
Urine chloride decreased 38.15 16.51 8 14740 78 50590298
Joint swelling 36.44 16.51 13 14735 245273 50345103
Metabolic alkalosis 35.85 16.51 17 14731 2714 50587662
Urine sodium decreased 33.16 16.51 8 14740 153 50590223
Alopecia 33.12 16.51 15 14733 245032 50345344
Contraindicated product administered 32.45 16.51 3 14745 148955 50441421
Rash 30.90 16.51 50 14698 437421 50152955
Chest pain 29.77 16.51 116 14632 176766 50413610
Therapeutic product effect decreased 28.95 16.51 3 14745 136047 50454329
Oxygen consumption increased 28.92 16.51 16 14732 3520 50586856
Cardiac arrest 28.29 16.51 70 14678 83581 50506795
Blood creatinine increased 28.19 16.51 66 14682 76094 50514282
Pain in jaw 27.44 16.51 44 14704 38384 50551992
Weight increased 27.42 16.51 124 14624 201767 50388609
Cardiorenal syndrome 26.96 16.51 9 14739 570 50589806
Respiratory disorder 26.92 16.51 39 14709 31148 50559228
Synovitis 25.67 16.51 3 14745 123862 50466514
Hyperthyroidism 25.44 16.51 24 14724 12151 50578225
Pericardial haemorrhage 25.22 16.51 11 14737 1447 50588929
Pericardial effusion 25.06 16.51 34 14714 25555 50564821
Drug intolerance 24.43 16.51 17 14731 219087 50371289
Renal impairment 24.20 16.51 62 14686 75599 50514777
Blood urea increased 24.11 16.51 32 14716 23553 50566823
Dehydration 24.05 16.51 98 14650 152351 50438025
Bone density decreased 23.46 16.51 22 14726 11053 50579323
Paracentesis 22.93 16.51 9 14739 907 50589469
Arthropathy 22.38 16.51 9 14739 157897 50432479
Toxic epidermal necrolysis 22.26 16.51 29 14719 20963 50569413
Localised oedema 21.80 16.51 15 14733 4852 50585524
Atrial flutter 21.69 16.51 19 14729 8744 50581632
Neutropenia 21.69 16.51 8 14740 147957 50442419
Pulmonary arterial pressure increased 21.65 16.51 13 14735 3335 50587041
Discomfort 21.55 16.51 3 14745 108377 50481999
Multiple organ dysfunction syndrome 21.27 16.51 46 14702 50291 50540085
Abdominal distension 20.54 16.51 57 14691 72846 50517530
Musculoskeletal stiffness 20.49 16.51 6 14742 128475 50461901
Vascular parkinsonism 20.24 16.51 5 14743 106 50590270
Oxygen therapy 19.94 16.51 10 14738 1802 50588574
Orthopnoea 19.70 16.51 15 14733 5674 50584702
Cellulitis 19.60 16.51 55 14693 70743 50519633
Pulmonary arterial wedge pressure increased 19.46 16.51 6 14742 294 50590082
Chronic obstructive pulmonary disease 19.43 16.51 46 14702 53389 50536987
Oxygen saturation decreased 19.40 16.51 56 14692 73192 50517184
Device leakage 19.27 16.51 15 14733 5863 50584513
Blood aldosterone abnormal 18.81 16.51 4 14744 42 50590334
Elephantiasis 18.13 16.51 3 14745 6 50590370
Brain natriuretic peptide increased 18.07 16.51 13 14735 4514 50585862
Blood potassium increased 17.93 16.51 23 14725 16375 50574001
Hepatic enzyme increased 17.64 16.51 9 14739 137371 50453005
Renal disorder 17.63 16.51 30 14718 27475 50562901
Condition aggravated 17.53 16.51 147 14601 296911 50293465
Asthenia 17.32 16.51 155 14593 318887 50271489
Epistaxis 17.03 16.51 49 14699 63905 50526471
Restlessness 16.85 16.51 28 14720 25145 50565231
Pleural effusion 16.71 16.51 57 14691 81397 50508979
Haemodialysis 16.55 16.51 16 14732 8346 50582030

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure congestive 231.51 18.01 209 11160 76372 29486786
Acute kidney injury 166.65 18.01 334 11035 264933 29298225
Hypokalaemia 111.76 18.01 116 11253 50087 29513071
Fluid retention 107.95 18.01 82 11287 23478 29539680
Hypervolaemia 84.65 18.01 63 11306 17482 29545676
Pulmonary hypertension 83.54 18.01 64 11305 18544 29544614
Hypotension 81.51 18.01 209 11160 194145 29369013
Cardiac failure 73.91 18.01 119 11250 79168 29483990
Pulmonary arterial hypertension 60.59 18.01 37 11332 7412 29555746
Dyspnoea 58.57 18.01 264 11105 326468 29236690
Oedema peripheral 57.01 18.01 124 11245 103433 29459725
Oedema 53.99 18.01 72 11297 40411 29522747
Blood creatinine increased 52.75 18.01 107 11262 84995 29478163
Right ventricular failure 48.84 18.01 33 11336 7857 29555301
Chronic kidney disease 44.37 18.01 62 11307 36354 29526804
Blood potassium increased 44.10 18.01 40 11329 14611 29548547
Venous pressure jugular increased 41.05 18.01 14 11355 715 29562443
Weight increased 37.89 18.01 88 11281 76579 29486579
Hypovolaemia 36.81 18.01 28 11341 8017 29555141
Drug ineffective 36.60 18.01 52 11317 363118 29200040
Polyuria 34.52 18.01 26 11343 7336 29555822
Glomerular filtration rate decreased 34.38 18.01 31 11338 11235 29551923
Necrotising oesophagitis 33.25 18.01 11 11358 511 29562647
Renal failure 32.66 18.01 110 11259 118489 29444669
Generalised oedema 32.65 18.01 30 11339 11135 29552023
Off label use 32.37 18.01 41 11328 300759 29262399
Hyponatraemia 31.63 18.01 76 11293 67557 29495601
Blood pressure systolic decreased 31.02 18.01 19 11350 3825 29559333
Transfusion 30.34 18.01 24 11345 7274 29555884
Dehydration 30.34 18.01 105 11264 114643 29448515
Blood urea increased 30.05 18.01 45 11324 28067 29535091
Gastrointestinal haemorrhage 29.59 18.01 82 11287 79451 29483707
Venous pressure jugular decreased 28.85 18.01 6 11363 41 29563117
Syncope 28.42 18.01 82 11287 81289 29481869
Orthopnoea 25.69 18.01 18 11351 4542 29558616
Cellulitis 24.15 18.01 54 11315 45786 29517372
Blood potassium decreased 24.12 18.01 30 11339 15704 29547454
Peripheral swelling 22.02 18.01 64 11305 63675 29499483
Febrile neutropenia 21.72 18.01 8 11361 112232 29450926
Asthenia 21.58 18.01 149 11220 215101 29348057
Azotaemia 21.15 18.01 16 11353 4541 29558617
Dizziness 20.62 18.01 134 11235 189550 29373608
Blood loss anaemia 20.23 18.01 19 11350 7247 29555911
Chronic obstructive pulmonary disease 20.19 18.01 47 11322 40908 29522250
Atrial fibrillation 19.99 18.01 87 11282 105559 29457599
Brain natriuretic peptide increased 19.96 18.01 15 11354 4215 29558943
Burkholderia test positive 19.78 18.01 9 11360 990 29562168
Neutropenia 18.69 18.01 14 11355 131697 29431461
Acute respiratory failure 18.50 18.01 35 11334 26367 29536791

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure congestive 403.26 15.02 354 23359 130226 64344793
Fluid retention 314.81 15.02 222 23491 59384 64415635
Hypervolaemia 283.21 15.02 176 23537 38109 64436910
Pulmonary arterial hypertension 254.36 15.02 142 23571 25225 64449794
Acute kidney injury 233.86 15.02 511 23202 448729 64026290
Right ventricular failure 195.86 15.02 113 23600 21358 64453661
Pulmonary hypertension 165.98 15.02 133 23580 43006 64432013
Dyspnoea 161.23 15.02 603 23110 718071 63756948
Oedema 133.96 15.02 167 23546 91768 64383251
Hypokalaemia 126.81 15.02 188 23525 121715 64353304
Drug ineffective 124.70 15.02 78 23635 840169 63634850
Oedema peripheral 123.69 15.02 252 23461 210065 64264954
Cardiac failure 111.10 15.02 185 23528 132188 64342831
Hypotension 104.24 15.02 342 23371 380632 64094387
Off label use 97.56 15.02 56 23657 632750 63842269
Gastrointestinal haemorrhage 75.85 15.02 157 23556 132155 64342864
Chronic kidney disease 74.55 15.02 99 23614 57820 64417199
Blood creatinine increased 73.06 15.02 157 23556 135625 64339394
Renal failure 72.61 15.02 187 23526 181501 64293518
Transfusion 68.15 15.02 55 23658 17939 64457080
Death 67.88 15.02 353 23360 482352 63992667
Acute respiratory failure 66.82 15.02 87 23626 49847 64425172
Calcium deficiency 66.28 15.02 20 23693 718 64474301
Cardiac failure acute 61.99 15.02 50 23663 16294 64458725
Atrial fibrillation 59.20 15.02 167 23546 170922 64304097
Dyspnoea exertional 59.07 15.02 101 23612 73629 64401390
Blood potassium increased 56.22 15.02 58 23655 25922 64449097
Weight increased 55.03 15.02 188 23525 213160 64261859
Hypoxia 53.33 15.02 107 23606 88042 64386977
Pulmonary oedema 53.08 15.02 100 23613 78574 64396445
Blood urea increased 53.05 15.02 73 23640 44080 64430939
Blood potassium decreased 50.36 15.02 68 23645 40331 64434688
Dehydration 49.89 15.02 184 23529 216579 64258440
Neutropenia 48.46 15.02 14 23699 239610 64235409
Hospitalisation 47.55 15.02 93 23620 75114 64399905
Glomerular filtration rate decreased 46.57 15.02 46 23667 19526 64455493
Orthopnoea 45.79 15.02 33 23680 9101 64465918
Infusion related reaction 45.67 15.02 4 23709 164463 64310556
Rheumatoid arthritis 45.61 15.02 4 23709 164290 64310729
Generalised oedema 44.12 15.02 46 23667 20807 64454212
Hyperkalaemia 43.39 15.02 107 23606 101022 64373997
Polyuria 42.36 15.02 36 23677 12607 64462412
Metabolic alkalosis 42.12 15.02 23 23690 3905 64471114
Electrolyte imbalance 41.85 15.02 49 23664 25194 64449825
Hypovolaemia 39.85 15.02 38 23675 15448 64459571
Syncope 39.82 15.02 138 23575 157497 64317522
Pain in jaw 38.27 15.02 60 23653 40695 64434324
Cardiorenal syndrome 37.75 15.02 15 23698 1235 64473784
Arthralgia 37.29 15.02 66 23647 442194 64032825
Gout 36.22 15.02 42 23671 21371 64453648
Urine sodium decreased 36.01 15.02 10 23703 266 64474753
Urine chloride decreased 35.18 15.02 8 23705 91 64474928
Brain natriuretic peptide increased 34.70 15.02 26 23687 7607 64467412
Febrile neutropenia 34.36 15.02 13 23700 187644 64287375
Venous pressure jugular increased 34.16 15.02 14 23699 1249 64473770
Cor pulmonale 33.83 15.02 16 23697 2009 64473010
Hyponatraemia 33.32 15.02 125 23588 148214 64326805
Joint swelling 33.14 15.02 19 23694 215363 64259656
BRASH syndrome 32.93 15.02 10 23703 367 64474652
Cellulitis 32.92 15.02 92 23621 93565 64381454
Azotaemia 32.88 15.02 25 23688 7477 64467542
Treatment failure 32.00 15.02 3 23710 116813 64358206
Oxygen therapy 31.94 15.02 16 23697 2277 64472742
Respiratory failure 31.50 15.02 130 23583 161053 64313966
Necrotising oesophagitis 30.72 15.02 11 23702 679 64474340
Ascites 30.26 15.02 69 23644 61932 64413087
Asthenia 30.19 15.02 264 23449 427780 64047239
Chronic left ventricular failure 29.91 15.02 11 23702 733 64474286
Product use in unapproved indication 29.51 15.02 14 23699 176604 64298415
Torsade de pointes 29.27 15.02 34 23679 17329 64457690
Chronic obstructive pulmonary disease 29.23 15.02 74 23639 70974 64404045
Alopecia 27.89 15.02 13 23700 165677 64309342
Paracentesis 27.53 15.02 12 23701 1247 64473772
International normalised ratio increased 27.07 15.02 77 23636 79090 64395929
Oxygen consumption increased 26.33 15.02 18 23695 4563 64470456
Atrial flutter 26.27 15.02 34 23679 19346 64455673
Condition aggravated 25.88 15.02 229 23484 372197 64102822
Dermatitis exfoliative 25.87 15.02 25 23688 10327 64464692
Rash 25.53 15.02 85 23628 458464 64016555
Venous pressure jugular decreased 25.17 15.02 6 23707 85 64474934
Arthropathy 24.56 15.02 7 23706 120960 64354059
Blood sodium decreased 24.41 15.02 41 23672 29441 64445578
Cholecystitis 24.39 15.02 33 23680 19603 64455416
Pericardial effusion 24.14 15.02 48 23665 39206 64435813
Peripheral swelling 23.97 15.02 145 23568 209008 64266011
Chest pain 23.58 15.02 158 23555 235822 64239197
Pulmonary arterial pressure increased 23.25 15.02 16 23697 4100 64470919
White blood cell count decreased 22.78 15.02 15 23698 157822 64317197
Contraindicated product administered 22.34 15.02 6 23707 107823 64367196
Left ventricular failure 22.31 15.02 21 23692 8396 64466623
Musculoskeletal stiffness 21.78 15.02 9 23704 123197 64351822
Hypertension 21.53 15.02 39 23674 259222 64215797
Blood loss anaemia 21.43 15.02 26 23687 13866 64461153
Renal impairment 21.16 15.02 102 23611 134915 64340104
Pericardial haemorrhage 20.86 15.02 15 23698 4121 64470898
Respiratory disorder 20.83 15.02 43 23670 36068 64438951
Malignant neoplasm progression 20.35 15.02 8 23705 112863 64362156
Renal disorder 20.27 15.02 42 23671 35323 64439696
Completed suicide 20.25 15.02 32 23681 224382 64250637
Discomfort 19.87 15.02 3 23710 80875 64394144
Blood pressure systolic decreased 19.64 15.02 20 23693 8800 64466219
Bone density decreased 19.36 15.02 21 23692 9931 64465088
Vascular parkinsonism 19.22 15.02 5 23708 103 64474916
Localised oedema 19.18 15.02 18 23695 7173 64467846
Pulmonary arterial wedge pressure increased 19.17 15.02 7 23706 457 64474562
Oxygen saturation decreased 19.03 15.02 84 23629 107092 64367927
Systemic lupus erythematosus 18.79 15.02 3 23710 77609 64397410
Drug hypersensitivity 18.67 15.02 37 23676 237778 64237241
Abdominal distension 18.40 15.02 77 23636 95917 64379102
Blood pressure increased 18.18 15.02 22 23691 172530 64302489
Dizziness 17.98 15.02 239 23474 429924 64045095
Blood aldosterone abnormal 17.88 15.02 4 23709 42 64474977
Stomatitis 17.83 15.02 9 23704 109596 64365423
Gastrointestinal arteriovenous malformation 17.66 15.02 8 23705 911 64474108
Device leakage 17.06 15.02 18 23695 8248 64466771
Nasal congestion 16.61 15.02 54 23659 59604 64415415
Lower respiratory tract infection 16.58 15.02 7 23706 94607 64380412
Elephantiasis 16.57 15.02 3 23710 9 64475010
Catheter management 16.54 15.02 12 23701 3343 64471676
Urine output decreased 16.49 15.02 25 23688 16467 64458552
Overdose 16.12 15.02 21 23692 159545 64315474
Interstitial lung disease 15.93 15.02 8 23705 97724 64377295
Haemodialysis 15.83 15.02 25 23688 17052 64457967
Hypokalaemic syndrome 15.68 15.02 4 23709 76 64474943
Injection site pain 15.52 15.02 11 23702 111397 64363622
Paraesthesia 15.42 15.02 16 23697 134506 64340513
Pleural effusion 15.29 15.02 89 23624 126470 64348549
Dyspnoea at rest 15.28 15.02 15 23698 6314 64468705

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C03BA08 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, EXCL. THIAZIDES
Sulfonamides, plain
ATC C03EA12 CARDIOVASCULAR SYSTEM
DIURETICS
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
Low-ceiling diuretics and potassium-sparing agents
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175420 Thiazide-like Diuretic
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004232 Diuretics
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D049993 Sodium Chloride Symporter Inhibitors
CHEBI has role CHEBI:35498 diuretics
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:50184 ion-transport inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Renal Disease with Edema indication
Peripheral Edema due to Chronic Heart Failure indication
Pulmonary Edema due to Chronic Heart Failure indication
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hepatic encephalopathy contraindication 13920009 DOID:13413
Orthostatic hypotension contraindication 28651003
Hypokalemia contraindication 43339004
Pregnancy-induced hypertension contraindication 48194001
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Hypomagnesemia contraindication 190855004
Persistent vomiting contraindication 196746003
Acute pancreatitis contraindication 197456007 DOID:2913
Severe diarrhea contraindication 409587002
Azotemia contraindication 445009001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.66 acidic
pKa2 1.3 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 12 member 3 Transporter INHIBITOR CHEMBL CHEMBL
Solute carrier family 12 member 1 Transporter Kd 8.45 WOMBAT-PK
Carbonic anhydrase 7 Enzyme Ki 8.68 CHEMBL

External reference:

IDSource
D00431 KEGG_DRUG
4018161 VANDF
C0025854 UMLSCUI
CHEBI:64354 CHEBI
CHEMBL878 ChEMBL_ID
DB00524 DRUGBANK_ID
D008788 MESH_DESCRIPTOR_UI
4170 PUBCHEM_CID
4838 IUPHAR_LIGAND_ID
2627 INN_ID
TZ7V40X7VX UNII
203794 RXNORM
1440 MMSL
47402 MMSL
5101 MMSL
d00299 MMSL
002310 NDDF
22198003 SNOMEDCT_US
387123003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0185-0055 TABLET 5 mg ORAL ANDA 23 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0185-0055 TABLET 5 mg ORAL ANDA 23 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0185-5050 TABLET 2.50 mg ORAL ANDA 23 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0185-5050 TABLET 2.50 mg ORAL ANDA 23 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0185-5600 TABLET 10 mg ORAL ANDA 23 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0185-5600 TABLET 10 mg ORAL ANDA 23 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0378-6172 TABLET 2.50 mg ORAL ANDA 24 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0378-6173 TABLET 5 mg ORAL ANDA 24 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0378-6174 TABLET 10 mg ORAL ANDA 24 sections
metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0527-2215 TABLET 2.50 mg ORAL NDA AUTHORIZED GENERIC 24 sections
metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0527-2216 TABLET 5 mg ORAL NDA AUTHORIZED GENERIC 24 sections
metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0527-2217 TABLET 10 mg ORAL NDA AUTHORIZED GENERIC 24 sections
metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6915 TABLET 5 mg ORAL NDA authorized generic 24 sections
metolazone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6916 TABLET 2.50 mg ORAL NDA authorized generic 24 sections
METOLAZONE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7138 TABLET 2.50 mg ORAL ANDA 22 sections
METOLAZONE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7139 TABLET 5 mg ORAL ANDA 22 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 43353-890 TABLET 2.50 mg ORAL ANDA 24 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 43353-931 TABLET 5 mg ORAL ANDA 24 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 43353-999 TABLET 2.50 mg ORAL NDA AUTHORIZED GENERIC 24 sections
METOLAZONE Human Prescription Drug Label 1 46708-532 TABLET 2.50 mg ORAL ANDA 22 sections
METOLAZONE Human Prescription Drug Label 1 46708-533 TABLET 5 mg ORAL ANDA 22 sections
METOLAZONE Human Prescription Drug Label 1 46708-534 TABLET 10 mg ORAL ANDA 22 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 51079-023 TABLET 2.50 mg ORAL ANDA 24 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 51079-024 TABLET 5 mg ORAL ANDA 24 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 51407-431 TABLET 2.50 mg ORAL ANDA 12 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 51407-432 TABLET 5 mg ORAL ANDA 12 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 51407-433 TABLET 10 mg ORAL ANDA 12 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 54868-5056 TABLET 5 mg ORAL ANDA 23 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 54868-5104 TABLET 2.50 mg ORAL ANDA 23 sections
Metolazone HUMAN PRESCRIPTION DRUG LABEL 1 54868-5119 TABLET 10 mg ORAL ANDA 23 sections